{"id":5195,"date":"2024-11-15T19:37:36","date_gmt":"2024-11-15T19:37:36","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=poster&#038;p=5195"},"modified":"2025-10-15T06:34:48","modified_gmt":"2025-10-15T06:34:48","slug":"protect-subgroup-analysis-proteinuria","status":"publish","type":"poster","link":"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/protect-subgroup-analysis-proteinuria\/","title":{"rendered":"PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g"},"content":{"rendered":"<section class=\"o-hero-section o-hero--banner o-hero--blue o-hero--cropped\">\n        <div class=\"container\">\n        <div class=\"m-hero-inner m-hero-inner--post\">\n            <div class=\"m-breadcrumb\">\n                <nav class=\"breadcrumbs\" aria-label=\"breadcrumb\"><span><span><a href=\"https:\/\/clleancode.top\/travere-redesign\/\">Home<\/a><\/span><\/span><\/nav>            <\/div>\n            <h1 class=\"a-heading a-heading--h1 h-white\">PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g<\/h1>                    <\/div>\n    <\/div>\n<\/section>\n\n\n\n\r\n\t<section style=\"padding-top:0px;margin-top:calc(-180px * var(--scale));\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<div class=\"info-block info-block-publication search__container-publication search__container\">\n\t<div class=\"info-block-top\">\n\t\t<div>\n\t\t\t\t\t\t\t<div class=\"info-block-type\"><i class=\"icon2-journal\" aria-hidden=\"true\"><\/i> Oral presentation<\/div>\n\t\t\t\n\t\t\t\t\t\t\t<div class=\"info-block-type\">\n\t\t\t\t\t<i class=\"icon2-calendar\" aria-hidden=\"true\"><\/i> Published on October 25, 2024\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t<p>Topics:<\/p>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">Nephrology<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"a-tag\">IgAN<\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\t<div class=\"info-block-bottom\">\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tContributors<br \/><span>Kooienga L, Trimarchi H, Floege J et al.<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<div class=\"info-block-box\">\n\t\t\t\t\tPresented at:<br \/><span>ASN 2024<\/span><br \/><br \/><br \/>\n\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Presentation_PROTECT-proteinuria-subgroup-analysis.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"btn btn-outline\">View presentation<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\n\t\t<div class=\"info-block-share\">\n\t\t\tShare: \n\t\t\t<span>\n\t\t\t\t\t<a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-subgroup-analysis-proteinuria%2F&#038;text=PROTECT+Subgroup+Analysis%3A+Sparsentan+Provides+Clinical+Benefits+vs+Irbesartan+in+Patients+With+IgA+Nephropathy+With+Proteinuria+Above+and+Below+1+g%2Fg\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-x\" aria-label=\"Share on Twitter\"><\/a> \n\t<a href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-subgroup-analysis-proteinuria%2F&#038;title=PROTECT+Subgroup+Analysis%3A+Sparsentan+Provides+Clinical+Benefits+vs+Irbesartan+in+Patients+With+IgA+Nephropathy+With+Proteinuria+Above+and+Below+1+g%2Fg\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-linkedin-2\" aria-label=\"Share on LinkedIn\"><\/a> \n\t<a href=\"https:\/\/www.facebook.com\/sharer\/sharer.php?u=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-subgroup-analysis-proteinuria%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon-facebook\" aria-label=\"Share on Facebook\"><\/a> \n\t<a href=\"mailto:?subject=PROTECT%20Subgroup%20Analysis%3A%20Sparsentan%20Provides%20Clinical%20Benefits%20vs%20Irbesartan%20in%20Patients%20With%20IgA%20Nephropathy%20With%20Proteinuria%20Above%20and%20Below%201%20g%2Fg&#038;body=https%3A%2F%2Fclleancode.top%2Ftravere-redesign%2Fcongress-materials%2Fprotect-subgroup-analysis-proteinuria%2F\" target=\"_blank\" rel=\"noopener noreferrer\" class=\"icon2-email-2\" aria-label=\"Share via Email\"><\/a>\n\t\t\t<\/span>\n\t\t<\/div>\n\t<\/div>\n<\/div><\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-about-the-researc-h\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">About the researc<\/mark><\/span><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">h<\/mark><\/span><\/h2>\n\n\n\n<div class=\"pdf-block\">\n\t\t\t\t<iframe src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Presentation_PROTECT-proteinuria-subgroup-analysis.pdf\" frameborder=\"0\"><\/iframe>\n\t\t<div class=\"pdf-block--buttons\">\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Presentation_PROTECT-proteinuria-subgroup-analysis.pdf\" class=\"btn\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"View\">View<\/a>\n\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Presentation_PROTECT-proteinuria-subgroup-analysis.pdf\" class=\"btn btn-outline\" download aria-label=\"Download\">Download<\/a>\n\t<\/div>\n<\/div>\n\n\n<h3 class=\"wp-block-heading has-text-align-center has-heading-4-font-size\" id=\"h-summary\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\">Summary<\/mark><\/span><\/h3>\n\n\n\t<div class=\"feature-block feature-block--left\">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">Background<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><ul>\n<li>Sparsentan is a non-immunosuppressive, single-molecule, <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protective-mechanism-sparsentan-chronic-kidney-disease-models\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\">Dual Endothelin Angiotensin Receptor Antagonist (DEARA)<\/span><\/a> indicated to slow kidney function decline in patients with IgA nephropathy<sup>1-4<\/sup><\/li>\n<li>In the Phase 3 <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga-nephropathy-protect-2-year-results-from-a-randomised-active-controlled-phase-3-trial-2\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\">PROTECT trial<\/span><\/a>, sparsentan has demonstrated rapid and sustained proteinuria reduction and better kidney function preservation versus the maximum labeled dose of irbesartan<sup>5<\/sup><\/li>\n<li>Reduced proteinuria is associated with improved kidney survival<sup>6<\/sup><\/li>\n<li>All patients with IgA nephropathy, even those with proteinuria <1 g\/day are at <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/long-term-outcomes-in-iga-nephropathy-2\/\" target=\"_blank\" rel=\"noopener\"><span style=\"text-decoration: underline;\">risk for developing kidney failure within 10 years of diagnosis<\/span><\/a><sup>7<\/sup><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1.jpg\" >\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"320\" height=\"380\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1.jpg\" class=\"attachment-full size-full\" alt=\"PROTECT study logo\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1.jpg 320w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1-253x300.webp 253w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/poster-1-290x344.webp 290w\" sizes=\"auto, (max-width: 320px) 100vw, 320px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-heading-5-font-size\" id=\"h-aim\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\"><span class=\"fw-600\">Aim<\/span><\/mark><\/h4>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>To determine the treatment effects of sparsentan versus the maximum labeled dose irbesartan in patients with IgA nephropathy between patients subgroups with baseline urine protein-creatinine ratio (UPCR) &lt;1.0 and \u22651.0 g\/g<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"7659\" height=\"2453\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure.png\" class=\"attachment-full size-full\" alt=\"PROTECT trial design\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure.png 7659w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure-300x96.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure-1024x328.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure-768x246.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure-1536x492.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure-2048x656.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-trial-design_figure-290x93.webp 290w\" sizes=\"auto, (max-width: 7659px) 100vw, 7659px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color\"><strong>Figure. PROTECT study design<\/strong><\/mark><br><br>PROTECT is a large, international, randomized, double-blind, active-controlled Phase 3 trial to assess the efficacy and safety of sparsentan versus irbesartan. This analysis evaluates subgroups of UPCR &lt;1 versus \u22651 g\/g at baseline<sup>1<\/sup><br><br><sup>a<\/sup>95% and 97% of patients titrated to maximum labeled dose of sparsentan and irbesartan, respectively.<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>Participants were randomly assigned to the treatment, sparsentan or active-control, maximum labeled dose irbesartan group<sup>1<\/sup><br><br>Study included a 110-week double-blind treatment period and 4 weeks of no treatment. Interim analysis occurred at 36 weeks. Two-year follow-up occurred at 110 weeks. There was an inclusion criterion of urinary protein excretion (UPE) \u22651 g\/day at screening<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-key-findings\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Key findings<\/mark><\/span><\/h5>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Patient demographics and baseline characteristics were well balanced between treatment arms<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Sparsentan demonstrated superior rapid and sustained reductions in UPCR regardless of baseline UPCR levels versus maximum labeled dose irbesartan<sup>1<\/sup><br><br><br>Similarly, complete remission (CR) of proteinuria was achieved earlier and more frequently in patients treated with sparsentan versus maximum labeled dose irbesartan regardless of baseline UPCR level<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1921\" height=\"930\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2.png 1921w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2-300x145.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2-1024x496.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2-768x372.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2-1536x744.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/baseline-upcr-graphs-2-290x140.webp 290w\" sizes=\"auto, (max-width: 1921px) 100vw, 1921px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-navy-color\">Figure. LS mean change from baseline in UPCR for the population with UPCR &lt;1 g\/g and UPCR&nbsp;\u22651 g\/g<\/mark><\/strong><br><br>At Week 110, patients with a baseline UPCR &lt;1.0 g\/g showed a 34.4% reduction when treated with sparsentan versus a 13.9% increase with maximum labeled dose irbesartan<sup>1<\/sup><br><br>At Week 110, patients with a baseline UPCR \u22651.0 g\/g showed a 48.2% reduction when treated with sparsentan versus a 12.5% reduction with maximum labeled dose irbesartan<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>In patients with baseline UPCR &lt;1.0 g\/g, sparsentan led to a 42% relative reduction versus maximum labeled dose irbesartan with a ratio of 0.58 (95% CI: 0.43 to 0.77)<sup>1<\/sup><\/p>\n\n\n\n<p>In patients with baseline UPCR \u22651.0 g\/g, sparsentan led to a 41% relative reduction versus maximum labeled dose irbesartan with a ratio of 0.59 (95% CI: 0.47 to 0.75)<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\">Greater kidney function preservation with sparsentan was consistently seen regardless of baseline UPCR level<sup>1<\/sup><\/p>\n\n\n\n<p><br>Absolute change in estimated glomerular filtration rate (eGFR) from baseline to Week 110 was lower with sparsentan versus maximum labeled irbesartan<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1921\" height=\"952\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1.png 1921w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1-300x149.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1-1024x507.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1-768x381.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1-1536x761.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ls-mean-change-egfr-figure-1-290x144.webp 290w\" sizes=\"auto, (max-width: 1921px) 100vw, 1921px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-navy-color\">Figure. LS mean change from baseline in eGFR for the overall study, UPCR &lt;1 g\/g, and UPCR \u22651 g\/g populations<\/mark><\/strong><br><br>In the overall population, sparsentan demonstrated a difference of 3.7 mL\/min per 1.73 m<sup>2<\/sup>. In the population with baseline UPCR &lt;1.0 g\/g, sparsentan demonstrated a difference of 1.9 mL\/min per 1.73 m<sup>2<\/sup>. In the population with baseline UPCR \u22651.0 g\/g, sparsentan demonstrated a difference of 4.2 mL\/min per 1.73 m<sup>2<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>In the overall population, sparsentan demonstrated a -5.8 mL\/min per 1.73 m<sup>2<\/sup> decrease in eGFR versus a -9.5 mL\/min per 1.73 m<sup>2<\/sup> decrease with maximum labeled dose irbesartan (Difference: 3.7, 95% CI: 1.45 to 5.99)<sup>1<\/sup><br><br>In the population with baseline UPCR &lt;1.0 g\/g, sparsentan demonstrated a -4.1 decrease in eGFR versus a -6.0 mL\/min per 1.73 m<sup>2<\/sup> decrease with maximum labeled dose irbesartan (Difference: 1.9, 95% CI: 1.96 to 5.69)<sup>1<\/sup><\/p>\n\n\n\n<p>In the population with baseline UPCR \u22651.0 g\/g, sparsentan demonstrated a -7.1 mL\/min per 1.73 m<sup>2<\/sup> decrease in eGFR versus a -11.3 mL\/min per 1.73 m<sup>2 <\/sup>decrease with maximum labeled dose irbesartan (Difference: 4.2, 95% CI: 1.39 to 7.05)<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"paragraph-border\"><br>Sparsentan was well tolerated with a consistent safety profile comparable to maximum labeled dose irbesartan across baseline proteinuria subgroups<sup>1<\/sup><br><br>The most common adverse events (AEs) [\u226515% of patients in any group] were:&nbsp;<\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>COVID-19*<\/li>\n\n\n\n<li>Dizziness<\/li>\n\n\n\n<li>Headaches<\/li>\n\n\n\n<li>Hyperkalemia<\/li>\n\n\n\n<li>Hypertension<\/li>\n\n\n\n<li>Hypotension<\/li>\n\n\n\n<li>Peripheral edema<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block \">\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1.png\" data-fancybox=\"gallery\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1921\" height=\"606\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1.png\" class=\"attachment-full size-full\" alt=\"\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1.png 1921w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1-300x95.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1-1024x323.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1-768x242.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1-1536x485.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/protect-subgroup-teae-table-1-290x91.webp 290w\" sizes=\"auto, (max-width: 1921px) 100vw, 1921px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"icon2-search\"><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><br><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-navy-color\">Table. Treatment-emergent adverse events (TEAE) and treatment discontinuations due to an AE<\/mark><\/strong><br><br>In the population with baseline UPCR &lt;1.0 g\/g, 90% (69\/77) of patients on sparsentan and 85% (58\/68) of patients on maximum labeled dose irbesartan experienced a TEAE<sup>1<\/sup><\/p>\n\n\n\n<p><br>In the population with baseline UPCR \u22651.0 g\/g, 94% (118\/125) of patients on sparsentan and 89% (119\/134) of patients on maximum labeled dose irbesartan experienced a TEAE<sup>1<\/sup><\/p>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<details class=\"wp-block-details\"><summary><strong><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-blue-color is-layout-flow wp-block-details-is-layout-flow\">About the figure<\/mark><\/strong><\/summary>\n<p>In the population with baseline UPCR &lt;1.0 g\/g, 8% (6\/77) of patients on sparsentan and 3% (2\/68) of patients on maximum labeled dose irbesartan discontinued treatment due to an AE<sup>1<\/sup><br><br>In the population with baseline UPCR \u22651.0 g\/g, 10% (13\/125) of patients on sparsentan and 12% (16\/134) of patients on maximum labeled dose irbesartan discontinued treatment due to an AE<sup>1<\/sup><\/p>\n<\/details>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"feature-block feature-block--half\">\n\t\t\t\t\t\t\t<div class=\"feature-content\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<p class=\"has-heading-5-font-size\">Conclusions<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<p><p class=\"p1\">Sparsentan has demonstrated nephroprotective treatment effects that are consistent across baseline proteinuria levels in patients with IgA nephropathy<sup>1<\/sup><\/p>\n<p class=\"p1\">Regardless of baseline UPCR level, when compared to maximum labeled dose irbesartan, sparsentan<sup>1<\/sup>:<\/p>\n<ul>\n<li class=\"p1\">Achieved rapid and superior proteinuria<\/li>\n<li class=\"p1\">Reached CR earlier and more frequently<\/li>\n<li class=\"p1\">Demonstrated greater kidney function preservation<\/li>\n<li class=\"p1\">Was well tolerated with a comparable safety profile<\/li>\n<li class=\"p1\">The draft KDIGO guidelines recommend treating patients with IgA nephropathy with proteinuria levels >0.5 g\/day-data from this analysis support the use of sparsentan in patients traditionally considered low risk<sup>1,8<\/sup><\/li>\n<\/ul>\n<\/p>\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<div class=\"feature-image\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header.png\" >\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"1080\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header.png\" class=\"attachment-full size-full\" alt=\"World map and people\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/people-world-map_header-290x163.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center\" id=\"h-see-more-from-asn-2024\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-teal-color\"><span class=\"fw-600\">See more from ASN 2024<\/span><\/mark><\/h4>\n\n\n  <div class=\"carousel-posts poster-carousel swiper carousel-type-poster wp-block-grizzly-posts-carousel\">\n    <div class=\"swiper-wrapper\">\n      <div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy\u00a0\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy\u00a0<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/10\/ASN2024_Poster_PROTECT-PRO.pdf\" target=\"_blank\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Learn more: Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy\u00a0\">Learn more<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2025\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/protect-proteinuria-remission-egfr\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: Implications of Proteinuria Remission on Estimated Glomerular Filtration Rate Trajectory in Patients With IgA Nephropathy in PROTECT\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div><div class=\"swiper-slide\">\t<article class=\"m-card m-card--no-image \" aria-label=\"Congress material card: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t<div class=\"m-card__top\">\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon4 icon4-poster\"><\/i> Congress material\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-w-medium\">Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)<\/p>\n\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">\n\t\t\t\t\t \n\t\t\t\t\t\t\t\t\t\t2024\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-btns\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/congress-materials\/sparsentan-sglt2i-iga-nephropathy-protect-ole\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"Read more: Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)\">\n\t\t\t\t\t\t\t\t<span>Read more<\/span>\n\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/article>\n<\/div>    <\/div>\n    <div class=\"swiper-pagination\"><\/div>\n          <\/div>\n\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"newsletter\">\n\t<div class=\"newsletter-icon\">\n\t\t<span class=\"icon2-newsletter\"><\/span>\n\t<\/div>\n\t<div class=\"newsletter-text\">\n\t\t<p><strong>Sign up<\/strong> to receive scientific updates<br \/>\nfor healthcare professionals<br \/>\nfrom Travere Therapeutics.<\/p>\n\t<\/div>\n\t<div class=\"newsletter-form\">\n\t\t<script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\nvar gform;gform||(document.addEventListener(\"gform_main_scripts_loaded\",function(){gform.scriptsLoaded=!0}),document.addEventListener(\"gform\/theme\/scripts_loaded\",function(){gform.themeScriptsLoaded=!0}),window.addEventListener(\"DOMContentLoaded\",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>\"function\"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn(\"The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1.\"),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener(\"gform_main_scripts_loaded\",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener(\"gform\/theme\/scripts_loaded\",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener(\"DOMContentLoaded\",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook(\"action\",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook(\"filter\",o,r,e,t)},doAction:function(o){gform.doHook(\"action\",o,arguments)},applyFilters:function(o){return gform.doHook(\"filter\",o,arguments)},removeAction:function(o,r){gform.removeHook(\"action\",o,r)},removeFilter:function(o,r,e){gform.removeHook(\"filter\",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+\"_\"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){\"function\"!=typeof(t=o.callable)&&(t=window[t]),\"action\"==r?t.apply(null,e):e[0]=t.apply(null,e)})),\"filter\"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});\n\/* ]]> *\/\n<\/script>\n\n                <div class='gf_browser_gecko gform_wrapper gform-theme gform-theme--foundation gform-theme--framework gform-theme--orbital' data-form-theme='orbital' data-form-index='0' id='gform_wrapper_1' ><style>#gform_wrapper_1[data-form-index=\"0\"].gform-theme,[data-parent-form=\"1_0\"]{--gf-color-primary: #204ce5;--gf-color-primary-rgb: 32, 76, 229;--gf-color-primary-contrast: #fff;--gf-color-primary-contrast-rgb: 255, 255, 255;--gf-color-primary-darker: #001AB3;--gf-color-primary-lighter: #527EFF;--gf-color-secondary: #fff;--gf-color-secondary-rgb: 255, 255, 255;--gf-color-secondary-contrast: #112337;--gf-color-secondary-contrast-rgb: 17, 35, 55;--gf-color-secondary-darker: #F5F5F5;--gf-color-secondary-lighter: #FFFFFF;--gf-color-out-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-out-ctrl-light-rgb: 17, 35, 55;--gf-color-out-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-out-ctrl-light-lighter: #F5F5F5;--gf-color-out-ctrl-dark: #585e6a;--gf-color-out-ctrl-dark-rgb: 88, 94, 106;--gf-color-out-ctrl-dark-darker: #112337;--gf-color-out-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-color-in-ctrl: #fff;--gf-color-in-ctrl-rgb: 255, 255, 255;--gf-color-in-ctrl-contrast: #112337;--gf-color-in-ctrl-contrast-rgb: 17, 35, 55;--gf-color-in-ctrl-darker: #F5F5F5;--gf-color-in-ctrl-lighter: #FFFFFF;--gf-color-in-ctrl-primary: #204ce5;--gf-color-in-ctrl-primary-rgb: 32, 76, 229;--gf-color-in-ctrl-primary-contrast: #fff;--gf-color-in-ctrl-primary-contrast-rgb: 255, 255, 255;--gf-color-in-ctrl-primary-darker: #001AB3;--gf-color-in-ctrl-primary-lighter: #527EFF;--gf-color-in-ctrl-light: rgba(17, 35, 55, 0.1);--gf-color-in-ctrl-light-rgb: 17, 35, 55;--gf-color-in-ctrl-light-darker: rgba(104, 110, 119, 0.35);--gf-color-in-ctrl-light-lighter: #F5F5F5;--gf-color-in-ctrl-dark: #585e6a;--gf-color-in-ctrl-dark-rgb: 88, 94, 106;--gf-color-in-ctrl-dark-darker: #112337;--gf-color-in-ctrl-dark-lighter: rgba(17, 35, 55, 0.65);--gf-radius: 3px;--gf-font-size-secondary: 14px;--gf-font-size-tertiary: 13px;--gf-icon-ctrl-number: url(\"data:image\/svg+xml,%3Csvg width='8' height='14' viewBox='0 0 8 14' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M4 0C4.26522 5.96046e-08 4.51957 0.105357 4.70711 0.292893L7.70711 3.29289C8.09763 3.68342 8.09763 4.31658 7.70711 4.70711C7.31658 5.09763 6.68342 5.09763 6.29289 4.70711L4 2.41421L1.70711 4.70711C1.31658 5.09763 0.683417 5.09763 0.292893 4.70711C-0.0976311 4.31658 -0.097631 3.68342 0.292893 3.29289L3.29289 0.292893C3.48043 0.105357 3.73478 0 4 0ZM0.292893 9.29289C0.683417 8.90237 1.31658 8.90237 1.70711 9.29289L4 11.5858L6.29289 9.29289C6.68342 8.90237 7.31658 8.90237 7.70711 9.29289C8.09763 9.68342 8.09763 10.3166 7.70711 10.7071L4.70711 13.7071C4.31658 14.0976 3.68342 14.0976 3.29289 13.7071L0.292893 10.7071C-0.0976311 10.3166 -0.0976311 9.68342 0.292893 9.29289Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-select: url(\"data:image\/svg+xml,%3Csvg width='10' height='6' viewBox='0 0 10 6' fill='none' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath fill-rule='evenodd' clip-rule='evenodd' d='M0.292893 0.292893C0.683417 -0.097631 1.31658 -0.097631 1.70711 0.292893L5 3.58579L8.29289 0.292893C8.68342 -0.0976311 9.31658 -0.0976311 9.70711 0.292893C10.0976 0.683417 10.0976 1.31658 9.70711 1.70711L5.70711 5.70711C5.31658 6.09763 4.68342 6.09763 4.29289 5.70711L0.292893 1.70711C-0.0976311 1.31658 -0.0976311 0.683418 0.292893 0.292893Z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-icon-ctrl-search: url(\"data:image\/svg+xml,%3Csvg width='640' height='640' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cpath d='M256 128c-70.692 0-128 57.308-128 128 0 70.691 57.308 128 128 128 70.691 0 128-57.309 128-128 0-70.692-57.309-128-128-128zM64 256c0-106.039 85.961-192 192-192s192 85.961 192 192c0 41.466-13.146 79.863-35.498 111.248l154.125 154.125c12.496 12.496 12.496 32.758 0 45.254s-32.758 12.496-45.254 0L367.248 412.502C335.862 434.854 297.467 448 256 448c-106.039 0-192-85.962-192-192z' fill='rgba(17, 35, 55, 0.65)'\/%3E%3C\/svg%3E\");--gf-label-space-y-secondary: var(--gf-label-space-y-md-secondary);--gf-ctrl-border-color: #686e77;--gf-ctrl-size: var(--gf-ctrl-size-md);--gf-ctrl-label-color-primary: #112337;--gf-ctrl-label-color-secondary: #112337;--gf-ctrl-choice-size: var(--gf-ctrl-choice-size-md);--gf-ctrl-checkbox-check-size: var(--gf-ctrl-checkbox-check-size-md);--gf-ctrl-radio-check-size: var(--gf-ctrl-radio-check-size-md);--gf-ctrl-btn-font-size: var(--gf-ctrl-btn-font-size-md);--gf-ctrl-btn-padding-x: var(--gf-ctrl-btn-padding-x-md);--gf-ctrl-btn-size: var(--gf-ctrl-btn-size-md);--gf-ctrl-btn-border-color-secondary: #686e77;--gf-ctrl-file-btn-bg-color-hover: #EBEBEB;--gf-field-img-choice-size: var(--gf-field-img-choice-size-md);--gf-field-img-choice-card-space: var(--gf-field-img-choice-card-space-md);--gf-field-img-choice-check-ind-size: var(--gf-field-img-choice-check-ind-size-md);--gf-field-img-choice-check-ind-icon-size: var(--gf-field-img-choice-check-ind-icon-size-md);--gf-field-pg-steps-number-color: rgba(17, 35, 55, 0.8);}<\/style><div id='gf_1' class='gform_anchor' tabindex='-1'><\/div>\n                        <div class='gform_heading'>\n\t\t\t\t\t\t\t<p class='gform_required_legend'>&quot;<span class=\"gfield_required gfield_required_asterisk\">*<\/span>&quot; indicates required fields<\/p>\n                        <\/div><form method='post' enctype='multipart\/form-data' target='gform_ajax_frame_1' id='gform_1'  action='\/travere-redesign\/wp-json\/wp\/v2\/poster\/5195#gf_1' data-formid='1' novalidate>\n                        <div class='gform-body gform_body'><div id='gform_fields_1' class='gform_fields top_label form_sublabel_above description_below validation_below'><div id=\"field_1_2\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_2'>First Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_1_2' type='text' value='' class='large'    placeholder='First Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_3\" class=\"gfield gfield--type-text gfield--input-type-text gfield--width-half gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_3'>Last Name<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_text'><input name='input_3' id='input_1_3' type='text' value='' class='large'    placeholder='Last Name' aria-required=\"true\" aria-invalid=\"false\"   \/><\/div><\/div><div id=\"field_1_1\" class=\"gfield gfield--type-email gfield--input-type-email gfield--width-full gfield_contains_required field_sublabel_above gfield--no-description field_description_below hidden_label field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label' for='input_1_1'>Email<span class=\"gfield_required\"><span class=\"gfield_required gfield_required_asterisk\">*<\/span><\/span><\/label><div class='ginput_container ginput_container_email'>\n                            <input name='input_1' id='input_1_1' type='email' value='' class='medium'   placeholder='Your Email' aria-required=\"true\" aria-invalid=\"false\"  \/>\n                        <\/div><\/div><div id=\"field_1_4\" class=\"gfield gfield--type-captcha gfield--input-type-captcha gfield--width-full field_sublabel_above gfield--no-description field_description_below field_validation_below gfield_visibility_visible\"  ><label class='gfield_label gform-field-label screen-reader-text' for='input_1_4'><\/label><div id='input_1_4' class='ginput_container ginput_recaptcha' data-sitekey='6LdC-_4qAAAAAFq7fXBVZpv8VBlO518KAQ92yXpY'  data-theme='light' data-tabindex='-1' data-size='invisible' data-badge='bottomright'><\/div><\/div><\/div><\/div>\n        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_1' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe Now'  \/> <input type='hidden' name='gform_ajax' value='form_id=1&amp;title=&amp;description=&amp;tabindex=0&amp;theme=orbital&amp;styles=[]&amp;hash=19a707562f078a6ce83770354aeb3dd2' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_1' value='iframe' \/>\n            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_1' id='gform_theme_1' value='orbital' \/>\n            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_1' id='gform_style_settings_1' value='[]' \/>\n            <input type='hidden' class='gform_hidden' name='is_submit_1' value='1' \/>\n            <input type='hidden' class='gform_hidden' name='gform_submit' value='1' \/>\n            \n            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' \/>\n            <input type='hidden' class='gform_hidden' name='state_1' value='WyJbXSIsIjY5OGM1NmFiMTIxOTFmZGIyYmVmMjY3YTI3NzY4MjVkIl0=' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_1' id='gform_target_page_number_1' value='0' \/>\n            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_1' id='gform_source_page_number_1' value='1' \/>\n            <input type='hidden' name='gform_field_values' value='' \/>\n            \n        <\/div>\n                        <\/form>\n                        <\/div>\n\t\t                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_1' id='gform_ajax_frame_1' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'><\/iframe>\n\t\t                <script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n gform.initializeOnLoaded( function() {gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery('#gform_ajax_frame_1').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_1');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_1').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_1').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_1').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_1').removeClass('gform_validation_error');}setTimeout( function() { \/* delay the scroll by 50 milliseconds to fix a bug in chrome *\/ jQuery(document).scrollTop(jQuery('#gform_wrapper_1').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_1').val();gformInitSpinner( 1, 'https:\/\/clleancode.top\/travere-redesign\/wp-content\/plugins\/gravityforms\/images\/spinner.svg', false );jQuery(document).trigger('gform_page_loaded', [1, current_page]);window['gf_submitting_1'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_1').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_1').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [1]);window['gf_submitting_1'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_1').text());}else{jQuery('#gform_1').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger(\"gform_pre_post_render\", [{ formId: \"1\", currentPage: \"current_page\", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( \"gform_wrapper_1\" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( \"span\" );            visibilitySpan.id = \"gform_visibility_test_1\";            gformWrapperDiv.insertAdjacentElement( \"afterend\", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( \"gform_visibility_test_1\" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 1, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); \n\/* ]]> *\/\n<\/script>\n\t\t<div class=\"agreement\">\n\t\t\t<div id=\"agreement-box-newsletter\">\n\t\t\t\t<input type=\"checkbox\" id=\"agreement-check-newsletter\" \/>\n\t\t\t\t<label for=\"agreement-check-newsletter\"><\/label>\n\t\t\t\t<div id=\"agreement-box-tick-newsletter\">\n\t\t\t\t\t<span class=\"icon2-tick\"><\/span>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p>I understand that by checking this box and clicking &#8220;Subscribe now&#8221; I am submitting my contact information and I consent to receive company communications from Travere Therapeutics.<\/p>\n\t\t\t\t<p>All personal information will be processed by or on behalf of Travere to provide access to company information and engage in marketing activities. Travere will retain personal information only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal information is private and will not sell this personal information or disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the <a href=\"https:\/\/travere.com\/privacy\/\" target=\"_blank\" rel=\"noopener\">Travere  privacy policies<\/a>.<\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div id=\"invalid-newsletter\" class=\"invalid\">\n\t\t\t<div id=\"invalid-box-newsletter\">\n\t\t\t\t<span class=\"icon2-info-fill\"><\/span>\n\t\t\t<\/div>\n\t\t\t<div>\n\t\t\t\t<p><strong>Invalid email address.<\/strong><br \/>\n\t\t\t\tMake sure email is in correct format: <a href=\"\">name@example.com<\/a><\/p>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n<div style=\"height:40px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t<div class=\"event-related search__container\">\n\t\t<h4>Related Events<\/h4>\n\t\t<div class=\"search-items__grid\">\n\t\t\t\t\n\t<article class=\"m-card m-card--past \">            \n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"300\" height=\"169\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-Event-Page-Glomcon-2025-V00-01-20250729-300x169.webp\" class=\"a-img\" alt=\"GlomCon Hawaii 2025\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-Event-Page-Glomcon-2025-V00-01-20250729-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-Event-Page-Glomcon-2025-V00-01-20250729-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-Event-Page-Glomcon-2025-V00-01-20250729-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/08\/MCE1359-Travere-GMA-Website-Event-Page-Glomcon-2025-V00-01-20250729-1536x864.webp 1536w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>\t\t\t            \n\t\t\t<div class=\"m-badges\">\n\t\t\t\t<span class=\"a-badge a-badge--red\">\n\t\t\t\t\t<i class=\"icon4 icon4-event-past\"><\/i>\n\t\t\t\t\t<span class=\"h-white a-text--sm\">Past<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-dark-blue h-w-medium\">\n\t\t\t\t\t   September 22\u201325, 2025 \u2013 Oahu, HI\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tGlomCon Hawaii 2025\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/glomcon-hawaii-2025\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"View details for GlomCon Hawaii 2025\">\n\t\t\t\t<span>See event<\/span>\n\t\t\t<\/a>\n\t\t<\/div>\n\t<\/article>\n\n\t\n\t<article class=\"m-card m-card--past \">            \n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"300\" height=\"169\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604-300x169.webp\" class=\"a-img\" alt=\"19th International Conference on Endothelin (ET-19)\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604-290x163.webp 290w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604.webp 1920w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>\t\t\t            \n\t\t\t<div class=\"m-badges\">\n\t\t\t\t<span class=\"a-badge a-badge--red\">\n\t\t\t\t\t<i class=\"icon4 icon4-event-past\"><\/i>\n\t\t\t\t\t<span class=\"h-white a-text--sm\">Past<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-dark-blue h-w-medium\">\n\t\t\t\t\t   September 21\u201324, 2025 \u2013 South Carolina, Charleston\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\t19th International Conference on Endothelin (ET-19)\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/et-19-conference-2025\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"View details for 19th International Conference on Endothelin (ET-19)\">\n\t\t\t\t<span>See event<\/span>\n\t\t\t<\/a>\n\t\t<\/div>\n\t<\/article>\n\n\t\n\t<article class=\"m-card m-card--past \">            \n\t\t<div class=\"m-card__top\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"300\" height=\"169\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604_IIgANN-2025-banner-2-300x169.webp\" class=\"a-img\" alt=\"International Symposium on IgA Nephropathy (IIgANN)\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604_IIgANN-2025-banner-2-300x169.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604_IIgANN-2025-banner-2-1024x576.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604_IIgANN-2025-banner-2-768x432.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604_IIgANN-2025-banner-2-1536x864.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604_IIgANN-2025-banner-2-290x163.webp 290w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/07\/MCE1359-Travere-Digital-Innovation-Strategy-Website-PDP-Header-Banners-V00-03-20250604_IIgANN-2025-banner-2.webp 1920w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/>\t\t\t            \n\t\t\t<div class=\"m-badges\">\n\t\t\t\t<span class=\"a-badge a-badge--red\">\n\t\t\t\t\t<i class=\"icon4 icon4-event-past\"><\/i>\n\t\t\t\t\t<span class=\"h-white a-text--sm\">Past<\/span>\n\t\t\t\t<\/span>\n\t\t\t<\/div>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-dark-blue h-w-medium\">\n\t\t\t\t\t   September 17\u201320, 2025 \u2013 Prague, Czech Republic\t\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tInternational Symposium on IgA Nephropathy (IIgANN)\t\t\t\t<\/p>\n\t\t\t<\/div>\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/iigann-2025\/\" class=\"a-btn a-btn--secondary--blue\" aria-label=\"View details for International Symposium on IgA Nephropathy (IIgANN)\">\n\t\t\t\t<span>See event<\/span>\n\t\t\t<\/a>\n\t\t<\/div>\n\t<\/article>\n\n\t\t<\/div>\n\t\t<div class=\"event-related-btn\">\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/meetings-events\/\" class=\"btn\">See more<\/a>\n\t\t<\/div>\n\t<\/div>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h5 class=\"wp-block-heading\" id=\"h-footnotes\" style=\"margin-bottom:calc(30px * var(--scale))\"><span class=\"fw-600\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ocean-blue-color\">Footnotes<\/mark><\/span><\/h5>\n\n\n\n<p class=\"has-small-font-size\">PROTECT trial was conducted during the COVID-19 pandemic.<\/p>\n\n\n\n<p class=\"has-small-font-size\" style=\"margin-bottom:calc(30px * var(--scale))\"><br>AE, adverse event; CI, confidence interval; COVID-19, coronavirus disease 2019; DEARA, Dual Endothelin Angiotensin Receptor Antagonist; eGFR, estimated glomerular filtration rate; IgA, immunoglobulin A; IRB, irbesartan; KDIGO, Kidney Disease Improving Global Outcomes; LS, least square; SPAR, sparsentan; TEAE, treatment-emergent adverse event; UPCR, urine protein-creatinine ratio; <br>UPE, urinary protein excretion.<\/p>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ol class=\"wp-block-list\">\n<li class=\"has-small-font-size\">Kooienga I et al. Poster presented at: American Society of Nephrology Kidney Week 2024; October 23-27, 2024; San Diego, CA. FR-OR57.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Kohan DE et al. <em>Clin Sci<\/em>. 2024;138(11):645-662.<\/li>\n\n\n\n<li class=\"has-small-font-size\">FILSPARI\u00ae (sparsentan) Prescribing Information. San Diego, CA: Travere Therapeutics, Inc. 9\/2024.<\/li>\n\n\n\n<li class=\"has-small-font-size\">FILSPARI\u00ae (sparsentan) Summary of Product Characteristics. Paris, France: Vifor France. 7\/2024<\/li>\n\n\n\n<li class=\"has-small-font-size\">Rovin BH et al. <em>Lancet<\/em>. 2023;402(10417):2077-2090.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Thompson A et al. <em>Clin J Am Soc Nephrol<\/em>. 2019;14(3):469-481.<\/li>\n\n\n\n<li class=\"has-small-font-size\">Pitcher D et al. Clin J Am Soc Nephrol. 2023;18(6):727-738.<\/li>\n\n\n\n<li class=\"has-small-font-size\">KDIGO Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Accessed 22 October 2023. <a href=\"https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/kdigo.org\/wp-content\/uploads\/2024\/08\/KDIGO-2024-IgAN-IgAV-Guideline-Public-Review-Draft.pdf<\/a><\/li>\n<\/ol>\n<\/div>\n\n\n<p class=\"has-text-align-right\" style=\"margin-top:calc(30px * var(--scale));margin-bottom:calc(300px * var(--scale))\"><br>MA-SP-24-0133 | November 2024<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":0,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":"","pdf_file_link":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/11\/ASN2024_Presentation_PROTECT-proteinuria-subgroup-analysis.pdf"},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[175],"study_type":[],"resource_type":[200,180],"class_list":["post-5195","poster","type-poster","status-publish","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-protect","resource_type-presentation","resource_type-summary"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>PROTECT Subgroup Analysis: Proteinuria &lt;1.0 g\/g and \u22651.0 g\/g | Travere Medical Affairs<\/title>\n<meta name=\"description\" content=\"Learn more about the PROTECT Subgroup Analysis which evaluated clinical outcomes across baseline proteinuria levels. Read now.\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g\" \/>\n<meta property=\"og:description\" content=\"Learn more about the PROTECT Subgroup Analysis which evaluated clinical outcomes across baseline proteinuria levels. Read now.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T06:34:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-subgroup-analysis-proteinuria\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-subgroup-analysis-proteinuria\\\/\",\"name\":\"PROTECT Subgroup Analysis: Proteinuria &lt;1.0 g\\\/g and \u22651.0 g\\\/g | Travere Medical Affairs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"datePublished\":\"2024-11-15T19:37:36+00:00\",\"dateModified\":\"2025-10-15T06:34:48+00:00\",\"description\":\"Learn more about the PROTECT Subgroup Analysis which evaluated clinical outcomes across baseline proteinuria levels. Read now.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-subgroup-analysis-proteinuria\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-subgroup-analysis-proteinuria\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/posters\\\/protect-subgroup-analysis-proteinuria\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PROTECT Proteinuria Subgroup Analysis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"PROTECT Subgroup Analysis: Proteinuria &lt;1.0 g\/g and \u22651.0 g\/g | Travere Medical Affairs","description":"Learn more about the PROTECT Subgroup Analysis which evaluated clinical outcomes across baseline proteinuria levels. Read now.","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"PROTECT Subgroup Analysis: Sparsentan Provides Clinical Benefits vs Irbesartan in Patients With IgA Nephropathy With Proteinuria Above and Below 1 g\/g","og_description":"Learn more about the PROTECT Subgroup Analysis which evaluated clinical outcomes across baseline proteinuria levels. Read now.","og_url":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-15T06:34:48+00:00","twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/","url":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/","name":"PROTECT Subgroup Analysis: Proteinuria &lt;1.0 g\/g and \u22651.0 g\/g | Travere Medical Affairs","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"datePublished":"2024-11-15T19:37:36+00:00","dateModified":"2025-10-15T06:34:48+00:00","description":"Learn more about the PROTECT Subgroup Analysis which evaluated clinical outcomes across baseline proteinuria levels. Read now.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/posters\/protect-subgroup-analysis-proteinuria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"PROTECT Proteinuria Subgroup Analysis"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 12:15:25","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"product","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster\/5195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/poster"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=5195"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=5195"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=5195"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=5195"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=5195"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=5195"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=5195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}